β-Secretase-1: In Silico Drug Reposition for Alzheimer’s Disease (original) (raw)

Factors Influencing the Potency of Alzheimer Inhibitors: Computational and Docking Studies

American journal of Alzheimer's disease and other dementias, 2018

Beta-secretase as a target for Alzheimer’s disease drug discovery: an overview of in vitro methods for characterization of inhibitors

Vincenza Andrisano

Analytical and Bioanalytical Chemistry, 2011

View PDFchevron_right

Structure-Based Design of β‑Site APP Cleaving Enzyme 1 (BACE1) Inhibitors for the Treatment of Alzheimer's Disease

Shankar Venkatraman

View PDFchevron_right

Scaffold Morphing and In Silico Design of Potential BACE-1 (β-Secretase) Inhibitors: A Hope for a Newer Dawn in Anti-Alzheimer Therapeutics

krishna kumar mishra

Molecules

View PDFchevron_right

Boom in the development of non-peptidic β-secretase (BACE1) inhibitors for the treatment of Alzheimer's disease

Romano Silvestri

Medicinal Research Reviews, 2009

View PDFchevron_right

Emerging Alzheimer’s disease therapies: inhibition of β-secretase

Martin Citron

Neurobiology of Aging, 2002

View PDFchevron_right

Determination of Potential Multi-Target Inhibitors of Alzheimer’s Disease in Silico

Glendalyn Boothe

2019

View PDFchevron_right

Chronicles of Pharmaceutical Science Research Article Evaluation and Optimisation of in Silicon Designed B-Secretase Modulators for the Treatment of Alzheimer's Disease

Dr. Claire Shoemake

2017

View PDFchevron_right

In Silico Molecular Docking Approach Against Enzymes Causing Alzheimer's Disease Using Borassus flabellifer Linn

Samsoon Maharifa

Applied Biochemistry and Biotechnology, 2022

View PDFchevron_right

Structure guided P1′ modifications of HEA derived β-secretase inhibitors for the treatment of Alzheimer’s disease

Michael Bartberger

Bioorganic & Medicinal Chemistry Letters, 2012

View PDFchevron_right

Identifying Potential Bace-1 Enzyme Inhibitors /Lead Small Molecules: Relevance to Alzheimer's Diseases

Deepak Ganesh

Zenodo (CERN European Organization for Nuclear Research), 2022

View PDFchevron_right

β-Secretase inhibition for the treatment of Alzheimer's disease – promise and challenge

Martin Citron

Trends in Pharmacological Sciences, 2004

View PDFchevron_right

In silico molecular studies of natural compounds as possible anti-Alzheimer’s agents: ligand-based design

IBRAHIM MOMOH

Network Modeling Analysis in Health Informatics and Bioinformatics, 2020

View PDFchevron_right

Ensemble-Docking Approach on BACE-1: Pharmacophore Perception and Guidelines for Drug Design

Sandro Cosconati

ChemMedChem, 2007

View PDFchevron_right

Discovery of Novel Acetylcholinesterase Inhibitor Implication for the Design of New Anti-Alzheimer Agents

Amir Zeb

View PDFchevron_right

Targeting BACE 1(Beta secretase) through Polyphenolic compounds -A computational insilicoapproach with emphasis on binding site analysis

Sumathy Arunachalam

View PDFchevron_right

Dual Inhibitors of AChE and BACE-1 for Reducing Aβ in Alzheimer’s Disease: From In Silico to In Vivo

Amiram Goldblum

International Journal of Molecular Sciences

View PDFchevron_right

In-Silico Drug Identification in the Treatment of Neurodegenerative Disease; Alzheimer

Dr. PRASHANT K U M A R SINGH

View PDFchevron_right

?-secretase as a target for the treatment of Alzheimer's disease

Martin Citron

Journal of Neuroscience Research, 2002

View PDFchevron_right

Advances in the identification of γ-secretase inhibitors for the treatment of Alzheimer's disease

B. Imbimbo

Expert Opinion on Drug Discovery, 2012

View PDFchevron_right

Halogen‑directed drug design for Alzheimer's disease: a combined density functional and molecular docking study

Mohammad Mahfuz Ali Khan Shawan

View PDFchevron_right

β-Secretase (BACE1) Inhibitors with High in Vivo Efficacy Suitable for Clinical Evaluation in Alzheimer’s Disease

alessandra bergadano

Journal of Medicinal Chemistry, 2013

View PDFchevron_right

Molecular modeling, docking and ADMET studies applied to the design of a novel hybrid for treatment of Alzheimer's disease

Ivone Carvalho

Journal of Molecular Graphics and Modelling, 2006

View PDFchevron_right

Aminomethyl-Derived Beta Secretase (BACE1) Inhibitors: Engaging Gly230 without an Anilide Functionality

Gabriela Barreiro

Journal of medicinal chemistry, 2016

View PDFchevron_right

Discovery and initial optimization of 5,5′-disubstituted aminohydantoins as potent β-secretase (BACE1) inhibitors

Michael Malamas

Bioorganic & Medicinal Chemistry Letters, 2010

View PDFchevron_right

Rational drug repurposing for alzheimer’s treatment using in-silico ligand and structure-based approaches

Ravindra Wavhale

Brazilian Journal of Pharmaceutical Sciences, 2024

View PDFchevron_right

New theoretical model for the study of new β-secretase inhibitors

Jan-carlo Díaz

Proceedings of MOL2NET, International Conference on Multidisciplinary Sciences, 2015

View PDFchevron_right

Structure-based design and synthesis of macrocyclic peptidomimetic β-secretase (BACE-1) inhibitors

Ulf Neumann

Bioorganic & Medicinal Chemistry Letters, 2009

View PDFchevron_right

Design of novel amyloid β aggregation inhibitors using QSAR, pharmacophore modeling, molecular docking and ADME prediction

Aswathy Lilly

View PDFchevron_right

Current and novel therapeutic molecules and targets in Alzheimer’s disease

Awanish Kumar, Ashwini Kumar, Timir Tripathi

View PDFchevron_right

Recent insight into BACE1 as a potential target for treatment of Alzheimer's disease

Samia Mostafa

2021

View PDFchevron_right

β-Secretase-1: In Silico Drug Reposition for Alzheimer’s Disease (original) (raw)

Related papers